Bromide

Bromide

SCHEMBL4416367

C[n+]1ccn(Cn2cc[n+](C)c2)c1.[Br-].[Br-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 1/20 0.55
APAF1 O14727 1/20 0.55
NPC1 O15118 1/20 0.55
PLA2G1B P04054 1/20 0.55
HSP90AA1 P07900 1/20 0.55
MAPT P10636 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ATG4B Q9Y4P1 1/20 0.55
LMNA P02545 1/20 0.43
FDPS P14324 2/20 0.42
PON1 P27169 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL988007 0.97 SMN1; SMN2 (0.52) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Hydrochloric Acid SCHEMBL4417695 0.95 SMN1; SMN2 (0.50) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Iodide SCHEMBL4414352 0.95 SMN1; SMN2 (0.50) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL6403529 0.82
Bromide SCHEMBL193043 0.82
SCHEMBL15136817 0.81 SMN1; SMN2 (0.63) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Bromide SCHEMBL531200 0.80
Bromide SCHEMBL14765117 0.80 SMN1; SMN2 (0.74) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Water SCHEMBL4948875 0.80 SMN1; SMN2 (0.57) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Bromide SCHEMBL29479434 0.80 SMN1; SMN2 (0.81) SMN1; SMN2MEN1APAF1NPC1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3310790-B1 METHOD OF TARGETING MISMATCHED DNA USING PT(II) D8 SQUARE PLANAR METAL COMPLEXES UNIV HONG KONG (CN) 2021-12-01 EP disclosed
US-10378046-B2 Method of targeting mismatched DNA using d8 square planar metal complexes THE UNIVERSITY OF HONG KONG (CN) 2019-08-13 US disclosed
US-20160369354-A1 METHOD OF TARGETING MISMATCHED DNA USING d8 SQUARE PLANAR METAL COMPLEXES THE UNIVERSITY OF HONG KONG (CN) 2016-12-22 US disclosed
US-8940904-B2 Use of transition metal-carbene complexes which do not comprise any cyclometallation via non-carbenes in OLEDs BASF SE (DE) 2015-01-27 US disclosed
US-8247574-B2 Use of PT -and PD-BIS- and tetra-carbon complexes with bridged carbon ligands in OLEDs BASF SE (DE) 2012-08-21 US disclosed
US-20090326237-A1 USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS BASF SE (DE) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326237-A1 USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS PDCD1, PDCD1LG2, CD274 SMN1; SMN2 4711/4885MEN1 3251/4885APAF1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.